PARP1 and pulmonary arterial hypertension: As outlined in Figure 3, specific pharmacological inhibitors like ABT-888 (PARP1 inhibitor), SGI-1776 (PIM1 inhibitor), Benzarone (EYA3 inhibitor), and MK-8776 (CHK1 inhibitor) downregulate their target genes, leading to reduced proliferation and increased apoptosis, suggesting their therapeutic potential in PAH [49,67,70,73].